Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.048 | 0.6 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.016 | 0.6 |
mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | 0.028 | 0.7 |
mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.7 |
mRNA | lapatinib | UHNBreast | pan-cancer | AAC | 0.13 | 0.7 |